Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells

Plant Biotechnology Journal

Volumn 11, Issue 1, 2013, Pages 77-86

  Kwon, Kwang Chul ^a   Nityanandam, Ramya ^a   New, James S ^a   Daniell, Henry ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bioencapsulation; Lyophilization; Molecular farming; Plant made biopharmaceuticals; Therapeutic peptides; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG CARRIER; EXENDIN 4; INSULIN; PEPTIDE; PLANTIBODY; VENOM;

ANIMAL; ARTICLE; CHLOROPLAST; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; METHODOLOGY; MICROCAPSULE; MOLECULAR FARMING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PLANT LEAF; SECRETION (PROCESS); TOBACCO; TRANSGENIC PLANT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CAPSULES; CHLOROPLASTS; DIABETES MELLITUS, TYPE 2; DRUG CARRIERS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MICE; MOLECULAR FARMING; PEPTIDES; PLANT LEAVES; PLANTIBODIES; PLANTS, GENETICALLY MODIFIED; TOBACCO; VENOMS;

MUS; NICOTIANA TABACUM;

EID: 84871707549     PISSN: 14677644     EISSN: 14677652     Source Type: Journal    
DOI: 10.1111/pbi.12008     Document Type: Article

References (60)

1. Arlen, P., Falconer, R., Cherukumilli, S., Cole, A., Cole, A.M., Oishi, K.K. and Daniell, H. (2007) Field production and functional evaluation of chloroplast-derived interferon-alpha2b. Plant Biotechnol. J. 5, 511-525.
2. Arntzen, C.J. (2008) Using tobacco to treat cancer. Science, 321, 1052-1053.
3. Baggio, L.L. and Drucker, D.J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157.
4. Baggio, L.L., Huang, Q., Brown, T.J. and Drucker, D.J. (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes, 53, 2492-2500.
5. Barnhart, K.F., Christianson, D.R., Hanley, P.W., Driessen, W.H., Bernacky, B.J., Baze, W.B., Wen, S., Tian, M., Ma, J., Kolonin, M.G., Saha, P.K., Do, K.A., Hulvat, J.F., Gelovani, J.G., Chan, L., Arap, W. and Pasqualini, R. (2011) A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci. Transl. Med. 3, 108ra112.
6. Bellmann-Sickert, K. and Beck-Sickinger, A.G. (2010) Peptide drugs to target G protein-coupled receptors. Trends Pharmacol. Sci. 31, 434-441.
7. Bond, A. (2006) Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc. (Bayl. Univ. Med. Cent.) 19, 281-284.
8. Boyhan, D. and Daniell, H. (2011) Low-cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C-peptide. Plant Biotechnol. J. 9, 585-598.
9. Centers for Disease Control and Prevention. (2011) National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
10. Chia, C.W. and Egan, J.M. (2005) Biology and therapeutic potential of GLP-1 in the treatment of diabetes. Drug Discov. Today Dis. Mech. 2, 295-301.
11. Daniell, H. (2007) Transgene containment by maternal inheritance: effective or elusive? Proc. Natl. Acad. Sci. USA, 104, 6879-6880.
12. Daniell, H., Singh, N.D., Mason, H. and Streatfield, S.J. (2009a) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 14, 669-679.
13. Daniell, H., Ruiz, G., Denes, B., Sandberg, L. and Langridge, W. (2009b) Optimization of codon composition and regulatory elements for expression of human insulin like growth factor-1 in transgenic chloroplasts and evaluation of structural identity and function. BMC Biotechnol. 9, 33.
14. Davidson, J.A. (2009) Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve. Clin. J. Med. 76, S28-S38.
15. Davoodi-Semiromi, A., Schreiber, M., Nalapalli, S., Verma, D., Singh, N.D., Banks, R.K., Chakrabarti, D. and Daniell, H. (2010) Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol. J. 8, 223-242.
16. Doyle, M.E., Theodorakis, M.J., Holloway, H.W., Bernier, M., Greig, N.H. and Egan, J.M. (2003) The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul. Pept. 114, 153-158.
17. FDA drug safety information (2009) Information for healthcare professionals: reports of altered kidney function in patients using Exenatide (marketed as Byetta). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm (accessed July 2012).
18. Fernández-San Millán, A., Ortigosa, S.M., Hervás-Stubbs, S., Corral-Martínez, P., Seguí-Simarro, J.M., Gaétan, J., Coursaget, P. and Veramendi, J. (2008) Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J. 6, 427-441.
19. Fishman, P.H., Bradley, R.M., Hom, B.E. and Moss, J. (1983) Uptake and metabolism of exogenous gangliosides by cultured cells: effect of choleragen on the turnover of GM1. J. Lipid Res. 24, 1002-1011.
20. Gisby, M.F., Mellors, P., Madesis, P., Ellin, M., Laverty, H., O′Kane, S., Ferquson, M.W. and Day, A. (2011) A synthetic gene increases TGFβ3 accumulation by 75-fold in tobacco chloroplasts enabling rapid purification and folding into a biologically active molecule. Plant Biotechnol. J. 9, 618-628.
21. Hamman, J.H. and Steenekamp, J.H. (2011) Oral peptide drug delivery: strategies to overcome challenges. In Peptide Drug Discovery and Development: Translational Research in Academia and Industry (Castanho, M. and Santos, N., eds), pp. 71-90. Weinheim: WILEY-VCH.
22. Heckly, R.J. (1985) Principles of preserving bacteria by freeze-drying. Dev. Ind. Microbiol. 26, 379-395.
23. Hohmeier, H.E. and Newgard, C.B. (2004) Cell lines derived from pancreatic islets. Mol. Cell. Endocrinol. 228, 121-128.
24. Holmgren, J., Lönnroth, I., Månsson, J. and Svennerholm, L. (1975) Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc. Natl. Acad. Sci. USA, 72, 2520-2524.
25. Hupe-Sodmann, K., McGregor, G.P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., Zimmermann, B. and Voigt, K. (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 22, 149-156.
26. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083-1091.
27. Kieffer, T., McIntosh, C. and Pederson, R. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 136, 3585-3596.
28. Kolterman, O.G., Buse, J.B., Fineman, M.S., Gaines, E., Heintz, S., Bicsak, T.A., Taylor, K., Kim, D., Aisporna, M., Wang, Y. and Baron, A.D. (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type2 diabetes. J. Clin. Endocrinol. Metab. 88, 3082-3089.
29. Koya, V., Moayeri, M., Leppla, S.H. and Daniell, H. (2005) Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect. Immun. 73, 8266-8274.
30. Lam, S. and See, S. (2006) Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus. Cardiol. Rev. 14, 205-211.
31. Lee, S.B., Li, B., Jin, S. and Daniell, H. (2011) Expression and characterization of antimicrobial peptides Retrocyclin-101 and Protegrin-1 in chloroplasts to control viral and bacterial infections. Plant Biotechnol. J. 9, 100-115.
32. Limaye, A., Koya, V., Samsam, M. and Daniell, H. (2006) Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system. FASEB J. 20, 959-961.
33. Lovshin, J.A. and Drucker, D.J. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5, 262-269.
34. Ma, S. and Jevnikar, A.M. (2012) Induction of oral tolerance to treat autoimmune and allergic diseases by using transgenic plants. In: Molecular Farming in Plants: Recent Advances and Future Prospects (Wang, A. and Ma, S., eds), pp. 21-35. New York: Springer.
35. Masur, K., Tibaduiza, E.C., Chen, C., Ligon, B. and Beinborn, M. (2005) Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol. Endorinol. 19, 1373-1382.
36. McGregor, D.P. (2008) Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 8, 616-619.
37. Munck, P.C., Nielsen, M.S., Jacobsen, C., Tauris, J., Jacobsen, L., Gliemann, J., Moestrup, S.K. and Madsen, P. (1999) Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J. 18, 595-604.
38. Nityanandam, R. (2011) Expression and functional evaluation of exendin 4 fused to cholera toxin B subunit in tobacco chloroplast to treat type 2 diabetes. Master Thesis. University of Central Florida.
39. Odumosu, O., Payne, K., Baez, I., Jutzy, J., Wall, N. and Langridge, W. (2011a) Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. Immunobiology, 216, 447-456.
40. Odumosu, O., Nicholas, D., Payne, K. and Langridge, W. (2011b) Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. Vaccine, 29, 8451-8458.
41. Reed, S.G., Bertholet, S., Coler, R.N. and Friede, M. (2009) New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32.
42. Riddle, M.C., Henry, R.R., Poon, T.H., Zhang, B., Mac, S.M., Holcombe, J.H., Kim, D.D. and Maggs, D.G. (2006) Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. 22, 483-491.
43. Ruhlman, T., Ahangari, R., Devine, A., Samsam, M. and Daniell, H. (2007) Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts-oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol. J. 5, 495-510.
44. Ruhlman, T., Verma, D., Samson, N. and Daniell, H. (2010) The role of heterologous chloroplast sequence elements in transgene integration and expression. Plant Physiol. 152, 2088-2104.
45. Ryan, E.T. and Calderwood, S.B. (2000) Cholera vaccines. Clin. Infect. Dis. 31, 561-565.
46. Sánchez, J. and Holmgren, J. (2008) Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci. 65, 1347-1360.
47. Schägger, H. (2006) Tricine-SDS-PAGE. Nat. Protoc. 1, 16-22.
48. Scheen, A.J. (2003) Pathophysiology of type 2 diabetes. Acta Clin. Belg. 58, 335-341.
49. Skelin, M., Rupnik, M. and Cencic, A. (2010) Pancreatic beta cell lines and their applications in diabetes mellitus research. Altex, 27, 105-113.
50. Srinivasan, K. and Ramarao, P. (2007) Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 125, 451-472.
51. Stanford, M., Whittall, T., Bergmeier, L.A., Lindblad, M., Lundin, S., Shinnick, T., Mizushima, Y., Holmgren, J. and Lehner, T. (2004) Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin. Exp. Immunol. 137, 201-208.
52. Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Drucker, D.J., Bonner-Weir, S., Habener, J.F. and Egan, J.M. (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes, 49, 741-748.
53. Sun, J.B., Czerkinsky, C. and Holmgren, J. (2010) Mucosally induced immunological tolerance, regulatory T Cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol. 71, 1-11.
54. Verma, D., Samson, N.P., Koya, V. and Daniell, H. (2008) A protocol for expression of foreign genes in chloroplasts. Nat. Protoc. 3, 739-758.
55. Verma, D., Moghimi, B., LoDuca, P.A., Singh, H.D., Hoffman, B.E., Herzog, R.W. and Daniell, H. (2010) Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc. Natl. Acad. Sci. USA, 107, 7101-7106.
56. Wadia, J.S. and Dowdy, S.F. (2002) Protein transduction technology. Curr. Opin. Biotechnol. 13, 52-56.
57. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes. Diabetes Care, 27, 1047-1053.
58. Wilson, J.P. (1967) Surface area of the small intestine in man. Gut, 8, 618-621.
59. Young, A.A., Gedulin, B.R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B. and Denaro, M. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes, 48, 1026-1034.
60. Yusibov, V., Streatfiled, S.J. and Kushnir, N. (2011) Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum. Vaccin. 7, 313-321.